Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms

Integrative Clinical Genomics of Advanced Prostate Cancer

(2015) Dan Robinson et al.   CELL

Androgen pathway resistance in prostate cancer and therapeutic implications

(2015) Benjamin L Maughan et al.   EXPERT OPINION ON PHARMACOTHERAPY

Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors

(2015) Joanna L Gillis et al.   Oncotarget

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer

(2014) ShengYu Ku et al.   PLoS One

Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells

(2013) Nishant Gandhi et al.   CANCER BIOLOGY & THERAPY

NF- B2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants

(2013) N. Nadiminty et al.   MOLECULAR CANCER THERAPEUTICS

Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches

(2013) T Karantanos et al.   ONCOGENE

Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression

(2013) Ayesha A. Shafi et al.   STEROIDS

Hsp90: Still a viable target in prostate cancer

(2012) Margaret M. Centenera et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer

(2012) R. Hu et al.   CANCER RESEARCH

Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines

(2012) Y. Li et al.   CANCER RESEARCH

Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors

(2012) M. M. Centenera et al.   CLINICAL CANCER RESEARCH

Hsp90 inhibitors and drug resistance in cancer: The potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs

(2011) Xiangyi Lu et al.   BIOCHEMICAL PHARMACOLOGY

Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells

(2011) Jeffery D Eskew et al.   BMC CANCER

A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors

(2011) Gopa Iyer et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression

(2011) Y. Li et al.   CANCER RESEARCH

Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy

(2011) Changmeng Cai et al.   ENDOCRINE-RELATED CANCER

The AR dependent cell cycle: Mechanisms and cancer relevance

(2011) Matthew J. Schiewer et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Blockade of testicular and adrenal androgens in prostate cancer treatment

(2011) Fernand Labrie   Nature Reviews Urology

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant

(2010) Shihua Sun et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I Pharmacokinetic and Pharmacodynamic Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an Inhibitor of Heat-Shock Protein 90, in Patients With Advanced Solid Tumors

(2010) Ramesh K. Ramanathan et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

(2010) Howard I Scher et al.   LANCET

Modulation of Hsf1 activity by novobiocin and geldanamycin

(2009) Renaud Conde et al.   Biochemistry and Cell Biology

A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth

(2009) Z. Guo et al.   CANCER RESEARCH

Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer

(2009) Qianben Wang et al.   CELL

ChIP-seq: Using high-throughput sequencing to discover protein–DNA interactions

(2009) Dominic Schmidt et al.   METHODS

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

(2009) C. Tran et al.   SCIENCE

Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance

(2008) S. M. Dehm et al.   CANCER RESEARCH

NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis

(2008) S. A. Eccles et al.   CANCER RESEARCH

A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer

(2008) E. I. Heath et al.   CLINICAL CANCER RESEARCH

Targeting the androgen receptor pathway in prostate cancer

(2008) Yu Chen et al.   CURRENT OPINION IN PHARMACOLOGY